Discovery, Prevention, Therapeutics. One of the Global Center's main R&D strategies is to combine the knowledge and practices of multiple scientific and clinical research disciplines to attack the highly prevalent, complex communication and biomedical problems of hearing impairment, deafness, age-related hearing loss, communication systems, speech perception, and voice quality. These multiple disciplines include audiology, bioengineering, biochemistry, biomedical imaging, cellular and molecular biology, electrical engineering, electrophysiology, gene therapy, genetics, microsystems engineering, neurophysiology, neuroanatomy, psychoacoustics, signal processing, speech science, and voice science.
Title & Aims | Sponsor | Investigators |
---|---|---|
Genetic Susceptibility and Biomarkers of Platinum-Related Toxicities Determine relations between platinum-induced hearing loss, neuropathy and genetics for testicular cancer survivors. |
NIH-National Cancer Institute (NCI) | Lois Travis, M.D., Sc.D. Robert Frisina, Ph.D. |
Elucidation of Under-Investigated Biological Mechanisms of Age-Related Hearing Loss Investigate autophagy pathways in the inner ear to prevent or treat acquired hearing loss, focusing upon age-related hearing loss. |
NIH-National Inst. for Deafness & Communication Disorders (NIDCD) | Robert Frisina, Ph.D. Bo Ding, M.D. |
Aging auditory system: Presbycusis and its neural bases Determine and characterize the perceptual, neural and molecular bases of age-related hearing loss in humans and animal models to move towards better technological and biotherapeutic translational research interventions. |
NIH-National Institute on Aging (NIA) | Robert Frisina, Ph.D. Joseph Walton, Ph.D. David Eddins, Ph.D. Ann Eddins, Ph.D |
Enabling Microsystem Technologies for Advanced Drug Delivery Develop novel microsystems and programmable micropumps for local drug delivery to targeted organ systems, starting with drug delivery to the inner ear to prevent or treat hearing, deafness and balance problems. |
NIH- National Institute on Deafness & Communication Disorders | Robert Frisina, Ph.D.; David Borkholder, Ph.D.; Joseph Walton, Ph.D. |
A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study] Conduct FDA Phase 2 Clinical Trials on a new drug that modulates Kv3.1 voltage-gated potassium channels in the central auditory system. |
Autifony Therapeutics | Robert Frisina, Ph.D.; Victoria Sanchez, Ph.D., Au.D.; Paul Boyev, M.D.; Theresa Chisholm, Ph.D. |